Safety Warning for levodopa/carbidopa drugs
FDA safety update (March 2026): vitamin B6 deficiency and seizures
In March 2026 the FDA required a new label warning for all carbidopa/levodopa products — which includes Crexont and Vyalev above, as well as older formulations such as Sinemet, Rytary, and Stalevo. These medications can lower Vitamin B6 (pyridoxine) levels and interfere with Vitamin b12 (cobalamin) absorption. It is reported that the FDA identified 14 reports of seizures linked to B6 deficiency, all in patients taking more than 1,000 mg of levodopa per day. The FDA advises checking B6 levels before and during treatment and supplementing when needed. Do not change any medication or start a supplement on your own — talk with your neurologist and doctor.
This warning does not mention Madopar as this drug does not appear to be widely used outside Australia. It does not appear in American Parkinson's literature much, if not at all. Unlike the ones in the warning, Madopar does not contain carbidopa. As the warning appears to be related solely to levodopa in the drugs, it is reasonable to assume that Madopar would also be included.
For further information go to the American Parkinsons Disease Association (APDA). They published a report on their website on 1 April, 2026. NOT an April Fools Day joke !!

Great article that underpins the importance of asking your doctor to check your vitamin B levels.
Thanks David